WO1996040273A3 - Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures - Google Patents

Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures Download PDF

Info

Publication number
WO1996040273A3
WO1996040273A3 PCT/EP1996/002442 EP9602442W WO9640273A3 WO 1996040273 A3 WO1996040273 A3 WO 1996040273A3 EP 9602442 W EP9602442 W EP 9602442W WO 9640273 A3 WO9640273 A3 WO 9640273A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
conjugates
target structures
ferrites
certain target
Prior art date
Application number
PCT/EP1996/002442
Other languages
French (fr)
Other versions
WO1996040273A2 (en
Inventor
Detlev Pfefferer
Mayk Kresse
Johannes Platzek
Ulrich Niedballa
Heinz Gries
Bernd Raduechel
Larry Gold
Original Assignee
Schering Ag
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Nexstar Pharmaceuticals Inc filed Critical Schering Ag
Priority to AU62224/96A priority Critical patent/AU6222496A/en
Priority to JP9500149A priority patent/JPH11507027A/en
Publication of WO1996040273A2 publication Critical patent/WO1996040273A2/en
Publication of WO1996040273A3 publication Critical patent/WO1996040273A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins

Abstract

This invention relates to new oligonucleotide conjugates, which contain a coated chemically modified ferrite as signal-transmitting group, on which oligonucleotides are bound by connecting components. In this case, the oligonucleotides are modified in a way that prevents or at least significantly inhibits the degradation by naturally occurring nucleases. The oligonucleotide can bond specifically and with high bonding affinity on target structures and can thus have a specific diagnostic and/or therapeutic effect on the ferrite.
PCT/EP1996/002442 1995-06-07 1996-06-05 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures WO1996040273A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU62224/96A AU6222496A (en) 1995-06-07 1996-06-05 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures
JP9500149A JPH11507027A (en) 1995-06-07 1996-06-05 Ferrite and oligonucleotide conjugates that specifically bind to specific target structures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47611695A 1995-06-07 1995-06-07
US08/476,116 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040273A2 WO1996040273A2 (en) 1996-12-19
WO1996040273A3 true WO1996040273A3 (en) 1997-03-27

Family

ID=23890573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002442 WO1996040273A2 (en) 1995-06-07 1996-06-05 Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures

Country Status (4)

Country Link
JP (1) JPH11507027A (en)
AU (1) AU6222496A (en)
WO (1) WO1996040273A2 (en)
ZA (1) ZA964871B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005815A1 (en) * 1985-03-25 1986-10-09 Genetics International Inc. Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences.
EP0295965A2 (en) * 1987-06-18 1988-12-21 Amoco Corporation Oscillator-based methods of detecting a member of a specific binding pair
US5160725A (en) * 1987-03-24 1992-11-03 Silica Gel Gesellschaft Mbh Adsorptions-Technik, Apparatebau Magnetic liquid compositions
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO1994001448A1 (en) * 1992-07-06 1994-01-20 Pharmagenics, Inc. Oligonucleotides modified with conjugate groups
EP0640350A2 (en) * 1991-09-16 1995-03-01 Syngenix Limited Ceramic particles and their preparation
DE4424922A1 (en) * 1994-07-14 1996-01-18 Schering Ag Nuclease-resistant oligo:nucleotide conjugates
WO1996002669A1 (en) * 1994-07-14 1996-02-01 Schering Aktiengesellschaft Conjugates of metal complexes and oligonucleotides, which specifically bond to specific target structures, agents containing these conjugates, their use in nmr diagnosis as well as process for their production
US5516670A (en) * 1991-09-30 1996-05-14 Kuehnle; Adelheid R. Magnetophoretic particle delivery method and apparatus for the treatment of cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005815A1 (en) * 1985-03-25 1986-10-09 Genetics International Inc. Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences.
US5160725A (en) * 1987-03-24 1992-11-03 Silica Gel Gesellschaft Mbh Adsorptions-Technik, Apparatebau Magnetic liquid compositions
EP0295965A2 (en) * 1987-06-18 1988-12-21 Amoco Corporation Oscillator-based methods of detecting a member of a specific binding pair
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0640350A2 (en) * 1991-09-16 1995-03-01 Syngenix Limited Ceramic particles and their preparation
US5516670A (en) * 1991-09-30 1996-05-14 Kuehnle; Adelheid R. Magnetophoretic particle delivery method and apparatus for the treatment of cells
WO1993023570A1 (en) * 1992-05-11 1993-11-25 Pharmagenics, Inc. Oligonucleotides having conjugates attached at the 2'-position of the sugar moiety
WO1994001448A1 (en) * 1992-07-06 1994-01-20 Pharmagenics, Inc. Oligonucleotides modified with conjugate groups
DE4424922A1 (en) * 1994-07-14 1996-01-18 Schering Ag Nuclease-resistant oligo:nucleotide conjugates
WO1996002669A1 (en) * 1994-07-14 1996-02-01 Schering Aktiengesellschaft Conjugates of metal complexes and oligonucleotides, which specifically bond to specific target structures, agents containing these conjugates, their use in nmr diagnosis as well as process for their production

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DEWANJEE MK ET AL: "Development of sensitive radioiodinated anti-sense oligonucleotide probes by conjugation technique.", BIOCONJUG CHEM, JUL-AUG 1991, VOL. 2, NO. 4, PAGE(S) 195-200, XP002024862 *
IVERSEN PL ET AL: "Binding of antisense phosphorothioate oligonucleotides to murine lymphocytes is lineage specific and inducible.", ANTISENSE RES DEV, FALL 1992, VOL. 2, NO. 3, PAGE(S) 223-33, XP000615946 *
KAIREMO KJ ET AL: "Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.", ANTICANCER DRUG DES, SEP 1996, VOL. 11, NO. 6, PAGE(S) 439-49, XP000615940 *
O'DONOGHUE JA: "Strategies for selective targeting of Auger electron emitters to tumor cells.", J NUCL MED, APR 1996, VOL. 37, NO. 4 SUPPL, PAGE(S) 3S-6S, XP002024863 *
PIRRUCCELLO SJ ET AL: "HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible.", ANTISENSE RES DEV, WINTER 1994, VOL. 4, NO. 4, PAGE(S) 285-9, XP002024861 *
TAKAKURA Y. ET AL: "Control of in vivo characteristics of gene and antisense DNA disposition", JPN. J. CANCER CHEMOTHER., 1994, VOL. 21, NO. 3, PAGE(S) 320-324, XP000615980 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV

Also Published As

Publication number Publication date
JPH11507027A (en) 1999-06-22
WO1996040273A2 (en) 1996-12-19
ZA964871B (en) 1997-02-06
AU6222496A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
HUP0004529A3 (en) Sulfonilated dipeptide-compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
WO2003059251A3 (en) Antibody targeting compounds
AU9781498A (en) Soft-tip high performance braided catheter
WO1999040112A8 (en) Neuroprotective peptides and uses thereof
EP1096040A3 (en) Chromate-free phosphate bonding composition
WO2003048207A3 (en) Anti-dota antibody
WO1999037678A3 (en) Antimicrobial peptides
WO1999056126A3 (en) Immuno-adsorption matrix, a method for the production thereof, and the utilization thereof
EP1892246A3 (en) Antimicrobial peptides and method for identifying and using such peptides
AU5305000A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO1996040273A3 (en) Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures
AU4373197A (en) Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
IL114237A0 (en) Oligonucleotide conjugates and diagnostic processes utilizing the same
WO1997047323A3 (en) Chitosan drug delivery system
WO2000064485A3 (en) Specifically targeted catalytic antagonists and uses thereof
GB9811221D0 (en) Bacterial-pheromones and uses therefor
ZA986242B (en) Specially shaped multilayer armour.
WO1999015542A3 (en) Linker nucleoside, and production and use of the same
WO2002100899A3 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
AU5619700A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
EP1649870A3 (en) Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
DE59505895D1 (en) Distributor or Delivery car
WO1999053091A3 (en) Dna coding for gdnf, parts of said dna and gdnf variants
ZA967817B (en) Phenylacetic acids, their preparation, and compositions comprising them.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BY CA CN CZ HU IL JP KR MX NO NZ PL RU SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BY CA CN CZ HU IL JP KR MX NO NZ PL RU SK UA VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996920793

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 500149

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1996920793

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase